Send to

Choose Destination
Clin Nucl Med. 2016 Sep;41(9):e417-9. doi: 10.1097/RLU.0000000000001264.

Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.

Author information

From the *Division of Radiology, Sirio-Libanes Hospital, Sao Paulo; †Division of Nuclear Medicine, Sirio-Libanes Hospital, Sao Paulo; and ‡Medical Oncology Center, Sirio-Libanes Hospital, Sao Paulo, Brazil.


A 64-year-old man with history of prostate adenocarcinoma underwent radical prostatectomy in 2003. He remained with undetectable prostate-specific antigen (PSA) levels until 2014, when he then presented rising serum PSA levels and performed a Tc-MDP bone scan that was negative for metastases. In August 2015, his PSA was 4.89 ng/dL, and restaging images with pelvic MR and F-FDG PET/CT were both negative. Therefore, the patient underwent a Ga-PSMA PET/CT that showed marked tracer uptake in a single mediastinal lymph node. Histopathology demonstrated metastatic adenocarcinoma secondary to prostate cancer, altering patient management to hormone therapy instead of pelvic radiotherapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center